| # | Title | Journal | Year | Citations |
|---|
| 1 | A Perivascular Niche for Brain Tumor Stem Cells | Cancer Cell | 2007 | 1,994 |
| 2 | DNA methylation-based classification of central nervous system tumours | Nature | 2018 | 1,872 |
| 3 | Acute lymphoblastic leukaemia | Lancet, The | 2008 | 1,308 |
| 4 | Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation | New England Journal of Medicine | 2009 | 1,059 |
| 5 | Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo | Molecular Therapy | 2009 | 988 |
| 6 | Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer | JAMA - Journal of the American Medical Association | 2013 | 965 |
| 7 | Acute lymphoblastic leukaemia | Lancet, The | 2013 | 879 |
| 8 | The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma | Nature Genetics | 2014 | 871 |
| 9 | Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia | Lancet Oncology, The | 2009 | 850 |
| 10 | The NLRP3 Inflammasome Protects against Loss of Epithelial Integrity and Mortality during Experimental Colitis | Immunity | 2010 | 830 |
| 11 | Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial | Lancet Oncology, The | 2006 | 811 |
| 12 | The whole-genome landscape of medulloblastoma subtypes | Nature | 2017 | 787 |
| 13 | New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs | Cell | 2016 | 702 |
| 14 | Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia | Cancer Cell | 2012 | 621 |
| 15 | The genomic landscape of hypodiploid acute lymphoblastic leukemia | Nature Genetics | 2013 | 588 |
| 16 | Recurrent Somatic Structural Variations Contribute to Tumorigenesis in Pediatric Osteosarcoma | Cell Reports | 2014 | 583 |
| 17 | NKAML: A Pilot Study to Determine the Safety and Feasibility of Haploidentical Natural Killer Cell Transplantation in Childhood Acute Myeloid Leukemia | Journal of Clinical Oncology | 2010 | 563 |
| 18 | Rearrangement of CRLF2 in B-progenitor– and Down syndrome–associated acute lymphoblastic leukemia | Nature Genetics | 2009 | 559 |
| 19 | Preventing and Managing Toxicities of High-Dose Methotrexate | Oncologist | 2016 | 550 |
| 20 | The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE) | Lancet, The | 2017 | 545 |
| 21 | Challenges to curing primary brain tumours | Nature Reviews Clinical Oncology | 2019 | 540 |
| 22 | Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy | Cancer Research | 2009 | 526 |
| 23 | Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | Nature | 2014 | 520 |
| 24 | Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial | Lancet Oncology, The | 2010 | 514 |
| 25 | Autophagy Links Inflammasomes to Atherosclerotic Progression | Cell Metabolism | 2012 | 509 |
| 26 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing | Clinical Pharmacology and Therapeutics | 2011 | 504 |
| 27 | The Immunology of Macrophage Activation Syndrome | Frontiers in Immunology | 2019 | 448 |
| 28 | Cancer health disparities in racial/ethnic minorities in the United States | British Journal of Cancer | 2021 | 447 |
| 29 | Preemptive Clinical Pharmacogenetics Implementation: Current Programs in Five US Medical Centers | Annual Review of Pharmacology and Toxicology | 2015 | 442 |
| 30 | Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? | Blood | 2012 | 439 |
| 31 | Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update | Clinical Pharmacology and Therapeutics | 2019 | 428 |
| 32 | Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair | Nature Cell Biology | 2007 | 421 |
| 33 | NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity | Nature Genetics | 2016 | 389 |
| 34 | PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia | Nature Genetics | 2019 | 384 |
| 35 | Primary B Cell Immunodeficiencies: Comparisons and Contrasts | Annual Review of Immunology | 2009 | 374 |
| 36 | Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms | Cancer Discovery | 2016 | 372 |
| 37 | Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia | Blood | 2012 | 368 |
| 38 | Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome | Clinical Cancer Research | 2017 | 358 |
| 39 | The landscape of somatic mutations in epigenetic regulators across 1,000 paediatric cancer genomes | Nature Communications | 2014 | 342 |
| 40 | Relapsed childhood acute lymphoblastic leukaemia | Lancet Oncology, The | 2013 | 338 |
| 41 | Current management and challenges of malignant disease in the CNS in paediatric leukaemia | Lancet Oncology, The | 2008 | 330 |
| 42 | AP-1 Transcription Factors and the BAF Complex Mediate Signal-Dependent Enhancer Selection | Molecular Cell | 2017 | 328 |
| 43 | Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial | Lancet Oncology, The | 2019 | 315 |
| 44 | The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure: A report from the childhood cancer survivor study | Pediatric Blood and Cancer | 2014 | 311 |
| 45 | Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update | Clinical Pharmacology and Therapeutics | 2013 | 304 |
| 46 | The SWI/SNF complex in cancer — biology, biomarkers and therapy | Nature Reviews Clinical Oncology | 2020 | 297 |
| 47 | Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase | Journal of Clinical Investigation | 2007 | 293 |
| 48 | Molecular Subtypes ofKIT/PDGFRAWild-Type Gastrointestinal Stromal Tumors | JAMA Oncology | 2016 | 291 |
| 49 | Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology | Acta Neuropathologica | 2016 | 288 |
| 50 | Glucocorticoid use in acute lymphoblastic leukaemia | Lancet Oncology, The | 2010 | 282 |
